Potential for partnerships The shutdown in 2024 suggests Aspen Clinical Research may be seeking to re-enter or reconfigure its business through new partnerships or buyouts. Target CROs, hospitals, or biopharma sponsors interested in expanding Phase II-IV clinical pharmacology capabilities or in acquiring an accredited 18-bed inpatient facility could be strategic targets.

Niche capacity Despite small size, the 20,000 square foot dedicated research center with inpatient capability represents a specialized asset for mid-stage trials and device studies. Focus on opportunities where a compact, in-house site supports faster patient recruitment and tight trial management for sponsors with moderate study scopes.

Full-service capabilities Aspen offered end-to-end support across therapeutic areas and trial phases, leveraging affiliations with other sites and CROs. This posture can be leveraged to offer bundled services or co-sourcing arrangements to larger sponsors seeking flexible, scalable clinical research options.

Financial footing Reported revenue in the mid-range for small providers indicates sustainable operations prior to closure. Potential buyers or partners might evaluate re-launch opportunities with cost-efficient infrastructure and a credible, proven clinical research footprint in Utah.

Market positioning Located in Orem, Utah with a specialized inpatient facility could position a new or renewed entity as a regional hub for Phase II-IV trials and device studies, enabling targeted outreach to regional biopharma, medical device firms, and sponsor networks seeking local site access and rapid enrollment.